We work worldwide to achieve our mission and vision responsibly and respond to our many stakeholders' needs and concerns. In order to realize this, we strive to be articulate and transparent in our positions and views on key policy issues which can impact our business and the people we serve.
Position on Health Technology Assessment
We believe that in a time where budgets for public healthcare are severely constrained, it is important to make socially responsible decisions about innovative medicines and treatments solutions by means of an assessment process which is transparent, open, fair and consistent.
Health Technology Assessment (HTA) is a process used in a growing number of countries which helps payers decide which medicines and treatments should be available for patients. The crucial question, however, is to identify what real additional value is for a patient and particularly for a person affected by a skin disease.
Our ambition and commitment is to be a constructive partner for national payers, HTA agencies, regulators, healthcare providers and patients in order to contribute to the development of processes for assessing the value of new medicines and treatments which can continue ensuring affordable access to innovative care for people with skin disease.
In order to address this challenge, LEO Pharma is committed to:
Always include the voice of patients through Patient-Reported Outcomes Measures (PROMs) into its future clinical trials. We believe that capturing patient inputs correctly is essential in order to understand the real burden of a skin disease and provide new medicines and treatments which can improve people quality of life.
Consistently support and communicates patients’ views to national payers and HTA agencies, and firmly believes that a transparent process should be established to incorporate patients’ inputs in HTA models.
Download full PDF version:
LEO Pharma position paper on Health Technology Assessment.